Plasma concentration of atrial natriuretic peptide at admission and risk of cardiac death in patients with acute myocardial infarction

Jens Svanegaard, Kristian Angelo-Nielsen, Torben Pindborg

Department of Clinical Chemistry, Svendborg Hospital, Svendborg, Denmark
Department of Cardiology and Internal Medicine, Svendborg Hospital, Svendborg, Denmark

Objective—To compare the concentration of plasma atrial natriuretic peptide in patients with acute myocardial infarction with a healthy population and to determine whether a raised concentration of plasma atrial natriuretic peptide at admission was a predictor of mortality after acute myocardial infarction.

Design—Patients with acute myocardial infarction were divided into a group with no congestion (class I) and a group with congestion (class II-IV) according to their highest Killip classification in the first 24 hours after infarction. The concentration of plasma atrial natriuretic peptide was measured at admission. On the basis of the concentration of atrial natriuretic peptide measured in the healthy population, patients were separated into two groups: a group with a high (>200 pg/ml) and a group with a low concentration of atrial natriuretic peptide (200 pg/ml). The patients were followed for three years.

Patients—55 patients admitted to the coronary care unit within 12 hours of the appearance of symptoms of acute myocardial infarction were compared with 51 healthy individuals.

Main outcome measures—Plasma atrial natriuretic pepetide, Killip class, mortality.

Results—The patients had significantly higher concentrations of atrial natriuretic peptide than the healthy controls. Furthermore, patients with congestion had a significantly higher concentration of atrial natriuretic peptide than the uncongested group of patients. Total mortality was 34·5%. In the group with a low concentration of atrial natriuretic peptide the mortality was only 13·6%, whereas mortality was significantly higher (48·5%) in the group with a high concentration.

Conclusions—The measurement of atrial natriuretic peptide separated the patients into low and high risk groups after acute myocardial infarction.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Yip, H.-K., Wu, C.-J., Chang, H.-W., Yang, C.-H., Yu, T.-H., Chen, Y.-H., Hang, C.-L. (2005). Prognostic Value of Circulating Levels of Endothelin-1 in Patients After Acute Myocardial Infarction Undergoing Primary Coronary Angioplasty. Chest 127: 1491-1497 [Abstract] [Full Text]  
• Rodeheffer, R. J. (2004). Measuring plasma B-type natriuretic peptide in heart failure: Good to go in 2004?. J Am Coll Cardiol 44: 740-749 [Abstract] [Full Text]  
• Tapanainen, J. M., Lindgren, K. S., Makikallio, T. H., Vuolteenaho, O., Leppaluoto, J., Huikuri, H. V. (2004). Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era. J Am Coll Cardiol 43: 757-763 [Abstract] [Full Text]  
• Ruskoaho, H. (2003). Cardiac Hormones as Diagnostic Tools in Heart Failure. Endocr. Rev. 24: 341-356 [Abstract] [Full Text]  
• Hakala, T., Hedman, A., Turpeinen, A., Kettunen, R., Vuolteenaho, O., Hippelainen, M. (2002). Prediction of atrial fibrillation after coronary artery bypass grafting by measuring atrial peptide levels and preoperative atrial dimensions. Eur. J. Cardiothorac. Surg. 22: 939-943 [Abstract] [Full Text]  
• Sigurdsson, A., Eriksson, S.V., Hall, C., Kahan, T., Swedberg, K. (2001). Early neurohormonal effects of trandolapril in patients with left ventricular dysfunction and a recent acute myocardial infarction: a double-blind, randomized, placebo-controlled multicentre study. Eur J Heart Fail 3: 69-78 [Abstract] [Full Text]  
• Fruhwald, F M, Fahrleitner, A, Watzinger, N, Dobnig, H, Schumacher, M, Maier, R, Zweiker, R, Leb, G, Klein, W (1999). N-terminal proatrial natriuretic peptide correlates with systolic dysfunction and left ventricular filling pattern in patients with idiopathic dilated cardiomyopathy. Heart 82: 630-633 [Abstract] [Full Text]  
• Fruhwald, F. M., Fahrleitner, A., Watzinger, N., Fruhwald, S., Dobnig, H., Schumacher, M., Maier, R., Zweiker, R., Klein, W. W. (1999). Natriuretic peptides in patients with diastolic dysfunction due to idiopathic dilated cardiomyopathy. Eur Heart J 20: 1415-1423 [Abstract]  
• Richards, A M, Nicholls, M G, Yandle, T G, Ikram, H, Espiner, E A, Turner, J G, Buttimore, R C, Lainchbury, J G, Elliott, J M, Frampton, C, Crozier, I G, Smyth, D W (1999). Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. Heart 81: 114-120 [Abstract] [Full Text]  
• Heeneman, S., Smits, J. F.M., Leenders, P. J.A., Schiffers, P. M.H., Daemen, M. J.A.P. (1997). Effects of Angiotensin II on Cardiac Function and Peripheral Vascular Structure During Compensated Heart Failure in the Rat. Arterioscler. Thromb. Vasc. Bio. 17: 1985-1994 [Abstract] [Full Text]  
• Bonow, R. O. (1996). New Insights Into the Cardiac Natriuretic Peptides. Circulation 93: 1946-1950 [Full Text]  
• Omland, T., Aakvaag, A., Bonarjee, V. V. S., Caidahl, K., Lie, R. T., Nilsen, D. W. T., Sundsfjord, J. A., Dickstein, K. (1996). Plasma Brain Natriuretic Peptide as an Indicator of Left Ventricular Systolic Function and Long-term Survival After Acute Myocardial Infarction : Comparison With Plasma Atrial Natriuretic Peptide and N-Terminal Proatrial Natriuretic Peptide. Circulation 93: 1963-1969 [Abstract] [Full Text]  
• Heeneman, S., Leenders, P. J. A., Aarts, P. J. J. W., Smits, J. F. M., Arends, J. W., Daemen, M. J. A. P. (1995). Peripheral Vascular Alterations During Experimental Heart Failure in the Rat : Do They Exist?. Arterioscler. Thromb. Vasc. Bio. 15: 1503-1511 [Abstract] [Full Text]